Free Trial
NASDAQ:NXGL

NEXGEL (NXGL) Stock Price, News & Analysis

NEXGEL logo
$2.97 -0.06 (-1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$3.00 +0.03 (+1.01%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NEXGEL Stock (NASDAQ:NXGL)

Key Stats

Today's Range
$2.91
$3.19
50-Day Range
$2.66
$3.82
52-Week Range
$1.84
$5.10
Volume
67,375 shs
Average Volume
64,704 shs
Market Capitalization
$20.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Remove Ads

NEXGEL Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
22nd Percentile Overall Score

NXGL MarketRank™: 

NEXGEL scored higher than 22% of companies evaluated by MarketBeat, and ranked 849th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for NEXGEL.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NEXGEL is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NEXGEL is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NEXGEL has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about NEXGEL's valuation and earnings.
  • Percentage of Shares Shorted

    1.99% of the float of NEXGEL has been sold short.
  • Short Interest Ratio / Days to Cover

    NEXGEL has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NEXGEL has recently decreased by 2.73%, indicating that investor sentiment is improving.
  • Dividend Yield

    NEXGEL does not currently pay a dividend.

  • Dividend Growth

    NEXGEL does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.99% of the float of NEXGEL has been sold short.
  • Short Interest Ratio / Days to Cover

    NEXGEL has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NEXGEL has recently decreased by 2.73%, indicating that investor sentiment is improving.
  • News Sentiment

    NEXGEL has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for NEXGEL this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for NXGL on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NEXGEL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,730.00 in company stock.

  • Percentage Held by Insiders

    24.86% of the stock of NEXGEL is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.21% of the stock of NEXGEL is held by institutions.

  • Read more about NEXGEL's insider trading history.
Receive NXGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NEXGEL and its competitors with MarketBeat's FREE daily newsletter.

NXGL Stock News Headlines

NEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Call Transcript
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
NEXGEL Reports Record Revenue Growth in 2024
NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript
See More Headlines

NXGL Stock Analysis - Frequently Asked Questions

NEXGEL's stock was trading at $4.46 at the beginning of the year. Since then, NXGL shares have decreased by 33.4% and is now trading at $2.97.
View the best growth stocks for 2025 here
.

NEXGEL, Inc. (NASDAQ:NXGL) issued its earnings results on Monday, March, 24th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. The firm earned $3.04 million during the quarter, compared to analyst estimates of $2.99 million. NEXGEL had a negative net margin of 52.60% and a negative trailing twelve-month return on equity of 71.19%.

NEXGEL (NXGL) raised $14 million in an initial public offering (IPO) on Wednesday, December 22nd 2021. The company issued 2,100,000 shares at a price of $6.83 per share. Maxim Group LLC acted as the underwriter for the IPO.

Top institutional investors of NEXGEL include Renaissance Technologies LLC (2.33%), Geode Capital Management LLC (0.89%), Two Sigma Securities LLC (0.18%) and IFP Advisors Inc (0.16%). Insiders that own company stock include John Nachum Stein, Nachum Stein, Adam R Levy, Steven Mark Glassman, Scott Robert Henry, Adam E Drapczuk III and David Stefansky.
View institutional ownership trends
.

Shares of NXGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NEXGEL investors own include Lexicon Pharmaceuticals (LXRX), Aditxt (ADTX), Helius Medical Technologies (HSDT), Onconova Therapeutics (ONTX), EchoStar (SATS), American Battery Technology (ABML) and Aumann (AAG).

Company Calendar

Last Earnings
3/24/2025
Today
3/26/2025
Next Earnings (Estimated)
4/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NXGL
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,160,000.00
Pretax Margin
-56.85%

Debt

Sales & Book Value

Annual Sales
$6.73 million
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
3.37

Miscellaneous

Free Float
5,103,000
Market Cap
$20.58 million
Optionable
Not Optionable
Beta
0.62
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:NXGL) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners